MD Imam Uddin
Last active: 3/30/2020


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ (2019) ACS Omega 4(5): 9251-9261
    › Primary publication · 31172046 (PubMed) · PMC6545551 (PubMed Central)
  2. Targeted Imaging of VCAM-1 mRNA in a Mouse Model of Laser-Induced Choroidal Neovascularization Using Antisense Hairpin-DNA-Functionalized Gold-Nanoparticles. Uddin MI, Kilburn TC, Yang R, McCollum GW, Wright DW, Penn JS (2018) Mol Pharm 15(12): 5514-5520
    › Primary publication · 30350640 (PubMed) · PMC7135968 (PubMed Central)
  3. Real-time imaging of VCAM-1 mRNA in TNF-α activated retinal microvascular endothelial cells using antisense hairpin-DNA functionalized gold nanoparticles. Uddin MI, Jayagopal A, Wong A, McCollum GW, Wright DW, Penn JS (2018) Nanomedicine 14(1): 63-71
    › Primary publication · 28890107 (PubMed) · PMC5742066 (PubMed Central)
  4. In Vivo Imaging of Retinal Hypoxia Using HYPOX-4-Dependent Fluorescence in a Mouse Model of Laser-Induced Retinal Vein Occlusion (RVO). Uddin MI, Jayagopal A, McCollum GW, Yang R, Penn JS (2017) Invest Ophthalmol Vis Sci 58(9): 3818-3824
    › Primary publication · 28750413 (PubMed) · PMC5531786 (PubMed Central)
  5. In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen-Induced Retinopathy. Uddin MI, Evans SM, Craft JR, Capozzi ME, McCollum GW, Yang R, Marnett LJ, Uddin MJ, Jayagopal A, Penn JS (2016) Sci Rep : 31011
    › Primary publication · 27491345 (PubMed) · PMC4974503 (PubMed Central)
  6. Nanoengineering of therapeutics for retinal vascular disease. Gahlaut N, Suarez S, Uddin MI, Gordon AY, Evans SM, Jayagopal A (2015) Eur J Pharm Biopharm 95(Pt B): 323-30
    › Primary publication · 26022642 (PubMed) · PMC4604030 (PubMed Central)
  7. Applications of azo-based probes for imaging retinal hypoxia. Uddin MI, Evans SM, Craft JR, Marnett LJ, Uddin MJ, Jayagopal A (2015) ACS Med Chem Lett 6(4): 445-9
    › Primary publication · 25893047 (PubMed) · PMC4394343 (PubMed Central)
  8. Molecular probes for imaging of hypoxia in the retina. Evans SM, Kim K, Moore CE, Uddin MI, Capozzi ME, Craft JR, Sulikowski GA, Jayagopal A (2014) Bioconjug Chem 25(11): 2030-7
    › Primary publication · 25250692 (PubMed) · PMC4240343 (PubMed Central)
  9. Synthesis and antimalarial activity of prodigiosenes. Marchal E, Smithen DA, Uddin MI, Robertson AW, Jakeman DL, Mollard V, Goodman CD, MacDougall KS, McFarland SA, McFadden GI, Thompson A (2014) Org Biomol Chem 12(24): 4132-42
    › Primary publication · 24834447 (PubMed)
  10. Microwave-assisted, one-pot reaction of 7-azaindoles and aldehydes: a facile route to novel di-7-azaindolylmethanes. Uddin MI, Buck JR, Schulte ML, Tang D, Saleh SA, Cheung YY, Harp J, Manning HC (2014) Tetrahedron Lett 55(1)
    › Primary publication · 24396154 (PubMed) · PMC3880151 (PubMed Central)
  11. Synthesis and biological evaluation of prodigiosene conjugates of porphyrin, estrone and 4-hydroxytamoxifen. Hawco CL, Marchal E, Uddin MI, Baker AE, Corkery DP, Dellaire G, Thompson A (2013) Bioorg Med Chem 21(19): 5995-6002
    › Primary publication · 23958515 (PubMed)
  12. Synthetic prodigiosenes and the influence of C-ring substitution on DNA cleavage, transmembrane chloride transport and basicity. Rastogi S, Marchal E, Uddin I, Groves B, Colpitts J, McFarland SA, Davis JT, Thompson A (2013) Org Biomol Chem 11(23): 3834-45
    › Primary publication · 23640568 (PubMed)
  13. Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging. Tang D, McKinley ET, Hight MR, Uddin MI, Harp JM, Fu A, Nickels ML, Buck JR, Manning HC (2013) J Med Chem 56(8): 3429-33
    › Primary publication · 23521048 (PubMed) · PMC3648642 (PubMed Central)
  14. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, Washington MK, Coffey RJ, Manning HC (2013) J Nucl Med 54(3): 424-30
    › Primary publication · 23341544 (PubMed) · PMC3633462 (PubMed Central)
  15. Rapid, Microwave-Assisted Organic Synthesis of Selective (V600E)BRAF Inhibitors for Preclinical Cancer Research. Buck JR, Saleh S, Uddin MI, Manning HC (2012) Tetrahedron Lett 53(32): 4161-4165
    › Primary publication · 23180892 (PubMed) · PMC3501741 (PubMed Central)